Data from a pooled analysis of three studies suggest that in patients with pain caused by diabetic nerve damage, or diabetic peripheral neuropathy, who are treated with Cymbalta (duloxetine HCl), improvements in both average daily pain and night pain severity were associated with less pain-related sleep interference than in those patients taking sugar pill.
Teva Pharmaceutical Industries Ltd. and Active Biotech AB announced that data from a 36-week, randomized, doubleblind, placebo-controlled Phase IIb study demonstrated that an oral 0.6 mg dose of laquinimod given daily significantly reduced magnetic resonance imaging (MRI) disease activity by 38 percent in RRMS patients and was well tolerated.
Bayer HealthCare Pharmaceuticals Inc, a U.S.-based pharmaceuticals unit of Bayer HealthCare., and Intendis Inc., a U.S.-based affiliate of Bayer Schering Pharma AG, Germany, announced today that they will jointly promote YAZ? (drospirenone/ethinyl estradiol) as a treatment for moderate acne in women who desire an oral contraceptive for birth control. The agreement came into effect on May 1, as part of an overall strategy to introduce dermatologists to the anti-acne benefits of YAZ.
Pharmaceuticals to update the existing black box warning on antidepressants’ labeling to include warnings about increased risks of suicidal thinking and behavior, known as suicidality, in young adults ages 18 to 24 during initial treatment, proposed by US FDA.
The U.S. Food and Drug Administration (FDA) proposed that makers of all antidepressant medications update the existing black box warning on their products’ labeling to include warnings about increased risks of suicidal thinking and behavior, known as suicidality, in young adults ages 18 to 24 during initial treatment (generally the first one to two months).
Genentech, Inc. (NYSE: DNA) and Biogen Idec, Inc. (Nasdaq: BIIB) announced that positive data from a Phase II clinical study of Rituxan? (rituximab) in patients with relapsing-remitting multiple sclerosis (RRMS) were presented at the American Academy of Neurology annual meeting held in Boston.
Recent findings that the widely-used herbal supplement Saint John?s wort could dramatically affect the absorption and metabolism of many prescription and non-prescription drugs raised concerns that other popular herbal supplements might cause similar changes, thus significantly altering drugs? therapeutic or toxic effects.
Data from two clinical trials presented today at the American Academy of Neurology meeting suggest that an investigational once daily extended release formulation of Lamictal (lamotrigine) is effective as add-on treatment in patients with partial epilepsy with and without secondary generalization.
Increasing the testosterone levels of female cancer survivors using testosterone cream did not improve their libido more than a placebo, according to a randomized controlled clinical trial in the May 2 Journal of the National Cancer Institute.
A promising anti-inflammatory drug failed to improve symptoms of moderate to severe chronic obstructive pulmonary disease, or COPD, in a large, multicenter trial.